posted March 28, 2022 08:15 am by AviseAnalytics
(4)
$ALGS Aligos Therapeutics, Inc. (NASDAQ: ALGS), a clinical-stage biotechnology company, has discontinued development of ALG-020572, intended for the treatment of chronic hepatitis B (CHB).
...read more